hATTR amyloidosis is an inherited, progressive disease caused by a genetic mutation that results in the buildup of misfolded transthyretin (TTR) protein. This results in the formation of amyloid deposits in the heart, nerves, and gastrointestinal tract. hATTR amyloidosis affects approximately 50,000 people worldwide. Many people remain undiagnosed or misdiagnosed.
Symptoms of hATTR amyloidosis vary from person to person, depending on which organs or tissues are affected. As the disease progresses, symptoms may worsen (eg, numbness or tingling of the feet can result in the need to walk with an aid or use a wheelchair) and can lead to significant disability, decreased quality of life, and, in many instances, a shortened lifespan.
HCPs: Want more information about this disease to share with patients? Start Here
While Alnylam provides financial support for this program, all tests and services are performed by independent third parties. Healthcare professionals must confirm that the patients meet certain criteria to use the program. Alnylam receives de-identified patient data from this program, but at no time does Alnylam receive patient-identifiable information. Alnylam receives contact information for healthcare professionals who use this program.
Download theAlnyam Act® Brochures for hATTR Amyloidosis